The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Abstract
PURPOSE: Serious cumulative toxicity is a well-recognized consequence of chemotherapy. Amifostine, an organic thiophosphate, has demonstrated the ability to protect selectively a broad range of normal, but not neoplastic, tissues from the cytotoxic effects of chemotherapy and radiotherapy. This study was designed to determine if amifostine could reduce the serious toxicities associated with cyclophosphamide and cisplatin (CP), without reducing antitumor efficacy in patients with ovarian cancer. PATIENTS AND METHODS: Two hundred forty-two patients with advanced ovarian cancer were randomized to receive six cycles of cyclophosphamide (1,000 mg/m2) and cisplatin (100 mg/m2) with or without amifostine (910 mg/m2) every 3 weeks for six cycles. The occurrence of hematologic, renal, neurologic, and ototoxicity was evaluated. Antitumor efficacy was assessed by pathologic tumor response and survival. RESULTS: Pretreatment with amifostine before each cycle of chemotherapy resulted in a reduction of cumulative toxicities. Hematologic toxicity consisted of grade 4 neutropenia associated with fever and/or infection that required antibiotic therapy (P = .005), days in hospital (P = .019), and days on antibiotics (P = .031). Platinum-specific toxicities consisted of protracted serum creatinine elevations (P = 0.004), > or = 40% reduction from baseline in creatinine clearance (P = .001), and severity of neurologic toxicity (P = .029). Twenty-four percent of CP patients compared with 9% of amifostine plus CP patients discontinued therapy because of protocol-specified toxicity (P = .002). Pathologic tumor response rates were 37% with amifostine and 28% in controls, with comparable median survival times of 31 months. Amifostine was generally well tolerated; the principal side effects were emesis and a transient decrease in blood pressure. CONCLUSION: Pretreatment with amifostine reduces the cumulative hematologic, renal, and neurologic toxicities associated with the CP regimen, with no reduction in antitumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
KINTZEL, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357
Alberts, D. S., Green, S., Hannigan, E. V., O’Toole, R. V., Stock-Novack, D., Anderson, P., Surwit, E. A., Malvlya, V. K., Nahhas, W. A., & Jolles, C. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.706 · Cited by 317
Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man
Dentino, M. E., Luft, F. C., Yum, M. N., Williams, S. D., & Einhorn, L. H. (1978) · Cancer · Cited by 305
Yuhas, J. M. (1980) · PubMed · Cited by 294
The role of WR-2721 in radiotherapy and/or chemotherapy.
Yuhas, J. M., Spellman, J. M., & Čulo, F. (1980) · PubMed · Cited by 281
Ifosfamide-pharmacology, safety and therapeutic potential
Brade, W. P., Herdrich, K., & Varini, M. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90011-8 · Cited by 243
Comprehensive Criteria for Assessing Therapy-Induced Toxicity
Ajani, J. A., Welch, S. R., Raber, M. N., Fields, W. S., & Krakoff, I. H. (1990) · Cancer Investigation · doi:10.3109/07357909009017560 · Cited by 232
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.574 · Cited by 192
Self-citationGerhartz, H., Engelhard, M., Meusers, P., Brittinger, G., Wilmanns, W., Schlimok, G., Mueller, P., Huhn, D., Musch, R., & Siegert, W. (1993) · Blood · doi:10.1182/blood.v82.8.2329.2329 · Cited by 170
Calabro-Jones, P. M., Fahey, R. C., Smoluk, G. D., & Ward, J. F. (1985) · International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine · doi:10.1080/09553008514550041 · Cited by 166
Jm, Y., & Čulo, F. (1980) · PubMed · Cited by 162
Hesketh, P. J., Harvey, W. H., Harker, W. G., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.596 · Cited by 132
Smoluk, G. D., Fahey, R. C., Calabro-Jones, P. M., Aguilera, J. A., & Ward, J. F. (1988) · PubMed · Cited by 131
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Glover, D. J., Glick, J. H., Weiler, C., et al. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.4.584 · Cited by 121
Self-citationDifferential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.
Th, W., Tl, P., Ross, G. Y., & Kane, L. J. (1981) · PubMed · Cited by 115
Yuhas, J. M., Spellman, J. M., Jordan, S. W., Pardini, M. C., Afzal, S., & Čulo, F. (1980) · British Journal of Cancer · doi:10.1038/bjc.1980.282 · Cited by 106
Cumulative renal tubular damage associated with cisplatin nephrotoxicity
Goren, M. P., Wright, R. K., & Horowitz, M. E. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253068 · Cited by 94
Human pharmacokinetics of WR-2721
Shaw, L. M. J., Turrisi, A. T., Glover, D. J., Bonner, H. S., Norfleet, A. L., Weiler, C., & Kligerman, M. M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90203-8 · Cited by 92
Milas, L., Hunter, N. R., Stephens, L. C., & Peters, L. J. (1984) · PubMed · Cited by 88
Shaw, L. M. J., Glover, D. J., Turrisi, A. T., Brown, D. Q., Bonner, H. S., Norfleet, A. L., Weiler, C., Glick, J. H., & Kligerman, M. M. (1988) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(88)90061-7 · Cited by 81
Self-citationTreskes, M., Nijtmans, L. G. J., Fichtinger-Schepman, A. M. J., & van der Vijgh, W. J. F. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90607-k · Cited by 80
Millar, J. L., McElwain, T. J., Clutterbuck, R. D., & Wist, E. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198206000-00015 · Cited by 75
Treskes, M., Boven, E., Holwerda, U., Pinedo, H. M., & van der Vijgh, W. J. F. (1992) · PubMed · Cited by 70
Acute and long-term nephrotoxicity of cis-platinum in man
Groth, S., Nielsen, H. J., S�rensen, J. B., Christensen, A. B., Pedersen, A. G., & R�rth, M. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00306754 · Cited by 69
Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
Valeriote, F. A., & Tolen, S. (1982) · PubMed · Cited by 64
Shpall, E. J., Stemmer, S. M., Hami, L., Franklin, W. A., Shaw, L. M. J., Bonner, H., Bearman, S., Peters, W., Bast, R. J., & McCulloch, W. F. (1994) · Blood · doi:10.1182/blood.v83.11.3132.3132 · Cited by 61
Treskes, M., Boven, E., van de Loosdrecht, A. A., Wijffels, J. F. A. M., Cloos, J. J., Peters, G. J., Pinedo, H. M., & van der Vijgh, W. J. F. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90084-1 · Cited by 60
Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies.
Jc, G.-V., Dm, H., Cvitkovic, E., & Ss, S. (1978) · PubMed · Cited by 59
Radiation Protectors: the Unexpected Benefits
Grdina, D. J., & Sigdestad, C. P. (1989) · Drug Metabolism Reviews · doi:10.3109/03602538908994143 · Cited by 57
Nagy, B., Dale, P. J., & Grdina, D. J. (1986) · PubMed · Cited by 56
Nagy, B., & Grdina, D. J. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90197-5 · Cited by 54
Kataoka, Y., Basic, I., Perrin, J., & Grdina, D. J. (1992) · International Journal of Radiation Biology · doi:10.1080/09553009214551081 · Cited by 52
Nephrotoxic and Ototoxic Agents
Walker, E. M., Fazekas‐May, M., & Bowen, W. R. (1990) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30572-9 · Cited by 45
The effect of cisplatin on renal function in patients with testicular tumours
MacLeod, P., Tyrell, C. J., & Keeling, D. H. (1988) · Clinical Radiology · doi:10.1016/s0009-9260(88)80022-9 · Cited by 36
Treskes, M., Holwerda, U., Nijtmans, L. G. J., Pinedo, H. M., & van der Vijgh, W. J. F. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684849 · Cited by 30
Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil
Peters, G. J., van der Wilt, C. L., Gyergyay, F., van Laar, J. A. M., Treskes, M., van der Vijgh, W. J. F., & Pinedo, H. M. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90524-l · Cited by 27
Alberts, D. S., Speicher, L. A., Krutzsch, M. F., et al. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00313-9 · Cited by 26
Swynnerton, N. F., Huelle, B. K., Mangold, D. J., & Ludden, T. M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90202-6 · Cited by 21
Measurement Of Ethiofos (Wr 2721) In Plasma: Preliminary Pharmaco-Kinetics in the Beagle
Swynnerton, N. F., Mangold, D. J., & Ludden, T. M. (1985) · Journal of Liquid Chromatography · doi:10.1080/01483918508076598 · Cited by 9
Cited by
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
Brizel, D. M., Wasserman, T. H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3339 · Cited by 828
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Metadata
- Authors
- Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-07
- Volume
- 14
- Issue
- 7
- Pages
- 2101-2112
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168284025
- Cited by
- 463
- References
- 44
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.